JP2011524421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524421A5 JP2011524421A5 JP2011514736A JP2011514736A JP2011524421A5 JP 2011524421 A5 JP2011524421 A5 JP 2011524421A5 JP 2011514736 A JP2011514736 A JP 2011514736A JP 2011514736 A JP2011514736 A JP 2011514736A JP 2011524421 A5 JP2011524421 A5 JP 2011524421A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- humanized
- corticosteroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 38
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 239000011230 binding agent Substances 0.000 claims 16
- 239000003246 corticosteroid Substances 0.000 claims 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000003080 antimitotic agent Substances 0.000 claims 8
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 8
- 229960004942 lenalidomide Drugs 0.000 claims 7
- 229960003957 dexamethasone Drugs 0.000 claims 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims 4
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims 4
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims 4
- 229960005558 mertansine Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 229940127121 immunoconjugate Drugs 0.000 claims 3
- -1 2-pyridyldithio Chemical group 0.000 claims 2
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 150000003573 thiols Chemical group 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 229930188224 Cryptophycin Natural products 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 108010006226 cryptophycin Proteins 0.000 claims 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 claims 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004412 neuroendocrine cell Anatomy 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6188608P | 2008-06-16 | 2008-06-16 | |
| US61/061,886 | 2008-06-16 | ||
| PCT/US2009/047449 WO2010008726A1 (en) | 2008-06-16 | 2009-06-16 | Novel synergistic effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011524421A JP2011524421A (ja) | 2011-09-01 |
| JP2011524421A5 true JP2011524421A5 (https=) | 2012-07-12 |
Family
ID=41550647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514736A Pending JP2011524421A (ja) | 2008-06-16 | 2009-06-16 | 新規の相乗効果 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8563700B2 (https=) |
| EP (1) | EP2300052A4 (https=) |
| JP (1) | JP2011524421A (https=) |
| KR (1) | KR20110028450A (https=) |
| CN (1) | CN102065891A (https=) |
| AU (1) | AU2009271401A1 (https=) |
| BR (1) | BRPI0914789A2 (https=) |
| CA (1) | CA2727278A1 (https=) |
| IL (1) | IL209911A0 (https=) |
| MX (1) | MX2010013833A (https=) |
| NZ (1) | NZ589880A (https=) |
| SG (1) | SG191679A1 (https=) |
| WO (1) | WO2010008726A1 (https=) |
| ZA (1) | ZA201009076B (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200503075B (en) * | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| CA2486285C (en) * | 2004-08-30 | 2017-03-07 | Viktor S. Goldmakher | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
| US20100172830A1 (en) * | 2007-03-29 | 2010-07-08 | Cellx Inc. | Extraembryonic Tissue cells and method of use thereof |
| NZ610239A (en) | 2008-04-30 | 2014-11-28 | Immunogen Inc | Cross-linkers and their uses |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| CA2761120A1 (en) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| AU2013201618B2 (en) * | 2009-05-06 | 2016-06-02 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| EP2490715A4 (en) * | 2009-10-21 | 2013-06-26 | Immunogen Inc | NEW DOSAGE ADMINISTRATION REGIMEN AND METHOD OF TREATMENT |
| SG181880A1 (en) | 2009-12-23 | 2012-07-30 | Gradalis Inc | Furin-knockdown and gm-csf-augmented (fang) cancer vaccine |
| RU2012131663A (ru) * | 2010-01-21 | 2014-02-27 | Иммьюноджен, Инк. | Композиции и способы лечения рака яичников |
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| SI2528625T1 (sl) * | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| DK2621531T3 (en) * | 2010-09-27 | 2017-02-27 | Morphosys Ag | ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL |
| EP3581206B8 (en) | 2010-10-22 | 2025-02-19 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| AU2012236210B2 (en) | 2011-04-01 | 2016-02-04 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| JP6104896B2 (ja) | 2011-06-01 | 2017-03-29 | アントフロゲネシス コーポレーション | 胎盤幹細胞を使用する疼痛の治療 |
| RU2014124984A (ru) * | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| KR20140100571A (ko) | 2011-12-08 | 2014-08-14 | 바이오테스트 아게 | Ｃｄ１３８을 타겟팅하는 면역접합체의 용도 |
| WO2013187967A1 (en) | 2012-06-15 | 2013-12-19 | Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") | Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control |
| WO2014004278A1 (en) | 2012-06-26 | 2014-01-03 | The Curators Of The University Of Missouri | Photocleavable drug conjugates |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| AU2014229529B2 (en) | 2013-03-13 | 2018-02-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| CN106456748A (zh) | 2014-01-08 | 2017-02-22 | 小利兰·斯坦福大学托管委员会 | 小细胞肺癌的靶向疗法 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3302561A4 (en) | 2015-06-08 | 2019-02-06 | Debiopharm International SA | COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES |
| KR102766022B1 (ko) | 2015-08-28 | 2025-02-10 | 데비오팜 인터네셔날 에스 에이 | Cd37 의 검출을 위한 항체 및 검정 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| US20180126000A1 (en) | 2016-06-02 | 2018-05-10 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| EP3535297B1 (en) | 2016-11-02 | 2022-08-10 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| RS61795B1 (sr) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
| CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| KR102270107B1 (ko) | 2017-08-18 | 2021-06-30 | 메디뮨 리미티드 | 피롤로벤조디아제핀 컨쥬게이트 |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| BR112020010694A2 (pt) | 2017-12-01 | 2020-11-10 | Abbvie Inc. | agonista de receptor de glicocorticoides e imunoconjugados do mesmo |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| KR20210006321A (ko) | 2018-01-12 | 2021-01-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 항-cd38 항체의 피하 투여 |
| EP3740233A4 (en) * | 2018-01-18 | 2021-11-24 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD134 + CELLS |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US12144818B2 (en) | 2018-05-30 | 2024-11-19 | Debiopharm International, S.A. | Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| BR112021014662A2 (pt) * | 2019-02-01 | 2021-09-21 | Glaxosmithkline Intellectual Property Development Limited | Tratamentos de combinação para o câncer que compreendem belantamab mafodotin e um anticorpo anti ox40 e usos e métodos dos mesmos |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| EP3980064A1 (en) | 2019-06-10 | 2022-04-13 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| CN120718855B (zh) * | 2025-09-03 | 2026-02-03 | 天津医科大学总医院 | 一种具有高淋巴结转移潜力的中国人肺大细胞神经内分泌癌细胞系及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843937A (en) * | 1996-05-23 | 1998-12-01 | Panorama Research, Inc. | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents |
| AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| ES2582652T3 (es) | 2006-02-10 | 2016-09-14 | Genentech, Inc. | Anticuerpos anti-FGF19 y métodos de uso de los mismos |
| AU2007281684C1 (en) * | 2006-08-07 | 2013-12-19 | Abbvie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
-
2009
- 2009-06-16 CA CA2727278A patent/CA2727278A1/en not_active Abandoned
- 2009-06-16 MX MX2010013833A patent/MX2010013833A/es not_active Application Discontinuation
- 2009-06-16 US US12/485,446 patent/US8563700B2/en not_active Expired - Fee Related
- 2009-06-16 NZ NZ589880A patent/NZ589880A/xx not_active IP Right Cessation
- 2009-06-16 BR BRPI0914789A patent/BRPI0914789A2/pt not_active IP Right Cessation
- 2009-06-16 EP EP09798415A patent/EP2300052A4/en not_active Withdrawn
- 2009-06-16 KR KR1020107028061A patent/KR20110028450A/ko not_active Withdrawn
- 2009-06-16 CN CN2009801225438A patent/CN102065891A/zh active Pending
- 2009-06-16 AU AU2009271401A patent/AU2009271401A1/en not_active Abandoned
- 2009-06-16 SG SG2013046396A patent/SG191679A1/en unknown
- 2009-06-16 WO PCT/US2009/047449 patent/WO2010008726A1/en not_active Ceased
- 2009-06-16 JP JP2011514736A patent/JP2011524421A/ja active Pending
-
2010
- 2010-12-09 IL IL209911A patent/IL209911A0/en unknown
- 2010-12-17 ZA ZA2010/09076A patent/ZA201009076B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524421A5 (https=) | ||
| Ab et al. | IMGN853, a folate receptor-α (FRα)–targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors | |
| JP2012522512A5 (https=) | ||
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| JP2012522513A5 (https=) | ||
| JP2014509835A5 (https=) | ||
| JP2019532056A5 (https=) | ||
| KR20170045351A (ko) | 신규한 항-mfi2 항체 및 사용 방법 | |
| JP2014139173A5 (https=) | ||
| JP2008546780A5 (https=) | ||
| JP2017048240A5 (https=) | ||
| JP2011519864A5 (https=) | ||
| CN110494448B (zh) | 包含抗-ly75抗体的医药组合 | |
| RU2017146345A (ru) | Анти-cd123 антитела и их конъюгаты и производные | |
| JP2017110002A5 (https=) | ||
| JP2018534933A5 (https=) | ||
| HRP20161029T1 (hr) | Protutijela anti-cd79b i imunokonjugati kao i postupci njihove uporabe | |
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| JP2017535257A5 (https=) | ||
| EP3292149A2 (en) | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof | |
| RU2008141171A (ru) | Анти-тат226 антитела и иммуноконъюгаты | |
| RU2016141267A (ru) | Антитела против egfr и конъюгаты антитело-лекарственное средство | |
| WO2019160751A3 (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| KR20170010764A (ko) | 신규한 항-ｒｎｆ43 항체 및 사용 방법 | |
| SI2424569T1 (en) | Immunoconjugated anti-mesothelin and their use |